Eleanor N. Dana Cancer Center

/centers/cancer/
/centers/cancer/

Services

/
 

Contact Us

Clinical trials at the Eleanor N. Dana Cancer Center

Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.


All Cancer Indications

Molecular Target Registry

+ More Info


Endocrine Cancer

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Identifier:  NCT03375320

Principal Investigator: Roland Skeel, MD

Ask Us About This Trial


Gastrointestinal Cancer

A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS

Identifier:  NCT05208047

Principal Investigator: Roland Skeel, MD

Ask Us About This Trial


Glioblastoma

Phase II of OKN-007 and TMZ in Recurrent Glioblastoma

Mechanism:  small molecule that targets heparin sulfate proteoglycans (HSPGs), can increase glioma tumor cell apoptosis and decrease proliferation and angiogenesis. It also increases vascular permeability, allowing drugs like temozolomide (TMZ) to accumulate in brain tissue.

+ More Info



Head and Neck, Colorectal Cancer

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant

Identifier:  NCT04885013

Principal Investigator: Divya Vijendra, MD

Ask Us About This Trial

Kidney Cancer

Phase III Trial of Immunotherapy-Based Combination Therapy with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Identifier:  NCT04510597

Principal Investigator: Firas Petros, MD

Ask Us About This Trial


Lung Cancer


Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy (KICKSTART)

Mechanism: Highly selective kinase inhibitor for MNK1 and MNK2

+ More Info

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Identifier:  NCT04533451

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Identifier:  NCT02194738

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO

Identifier:  NCT04267848

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant

Identifier:  NCT04885013

Principal Investigator:  Divya Vijendra, MD

Ask Us About This Trial

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO

Identifier:  NCT04267848

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial


Lymphomas

Phase 2b, Open-label, Randomized study of DPX-Survivac, Alone or with Pembrolizumab, with/out Cyclophosphamide, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

+ More Info


Pancreatic Cancer

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Identifier:  NCT043401412

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Identifier:  NCT04233866

Principal Investigator:  Roland Skeel, MD

Ask Us About This Trial


Prostate Cancer

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Identifier:  NCT04484818

Principal Investigator: Firas Petros, MD

Ask Us About This Trial


Solid Tumor

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info




Urothelial (Renal pelvis, Ureter, and Bladder Cancers)

Phase 3 of FGFR3 Inhibitor vs Placebo in Invasive Urothelial Carcinoma

Mechanism:  FGFR3 target

+ More Info

Phase 3 of CG0070 in Non-Muscule Invasive Bladder Cancer (NMIBC) unresponsive to BCG

Mechanism:  Biological, Engineered Oncolytic Adenovirus

+ More Info

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Identifier:  NCT03775265

Principal Investigator: Firas Petros, MD

Ask Us About This Trial


For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Jessica Obarski at 419.383.6972
/
Last Updated: 10/10/22